18 studies found for:    Open Studies | "Thymus Neoplasms"
Show Display Options
Rank Status Study
1 Recruiting Sunitinib for Advanced Thymus Cancer Following Earlier Treatment
Conditions: Thymoma;   Thymus Neoplasms
Intervention: Drug: Sunitinib
2 Recruiting Neoadjuvant Chemotherapy for Locally Advanced Thymic Cancer
Condition: Locally Advanced Stage III or IV Thymic Cancer
Intervention: Drug: neoadjuvant docetaxel/cisplatin
3 Recruiting Esophageal Sparing Intensity-modulated Radiation Therapy (IMRT) for Locally-Advanced Thoracic Malignancies
Conditions: Non Small Cell Lung Cancer;   Small Cell Lung Cancer;   Thymoma;   Thymus Neoplasms
Intervention: Radiation: Esophageal sparing IMRT
4 Recruiting Cancer Research Repository for Individuals With Cancer Diagnosis and High Risk Individuals.
Conditions: Pancreatic Cancer;   Thyroid Cancer;   Lung Cancer;   Esophageal Cancer;   Thymus Cancer
Intervention:
5 Recruiting A Phase II Study of Amrubicin in Relapsed or Refractory Thymic Malignancies
Conditions: Thymoma;   Thymus Cancer;   Thymic Carcinoma
Intervention: Drug: Amrubicin
6 Recruiting Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas
Conditions: Lung Cancer;   Esophageal Cancer;   Malignant Pleural Mesothelioma;   Sarcoma;   Thymic Carcinoma
Interventions: Biological: Allogeneic Tumor Cell Vaccine (K562);   Drug: Celecoxib;   Drug: cyclophosphamide
7 Recruiting Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies
Conditions: Carcinoma, Non-Small-Cell Lung;   Carcinoma, Small Cell Lung;   Carcinoma, Thymic
Interventions: Drug: AZD;   Drug: MK-2206;   Drug: Lapatinib;   Drug: Erlotinib;   Drug: Sunitinib;   Procedure: Molecular Profiling
8 Recruiting Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors
Conditions: Non-Small Cell Lung Cancer;   Small Cell Lung Cancer;   Extrapulmonary Small Cell Cancer;   Pulmonary Neuroendocrine Tumors;   Thymic Epithelial Tumors
Intervention:
9 Recruiting Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum
Conditions: Lung Cancer;   Esophageal Cancer;   Malignant Pleural Mesothelioma;   Sarcoma;   Thymic Carcinoma
Interventions: Biological: H1299 Lysate Vaccine;   Drug: Cyclophosphamide;   Drug: Celecoxib
10 Recruiting Postoperative Conformal Radiotherapy for Stage II-III B Type Thymoma
Condition: Thymoma
Intervention: Radiation: radiotherapy
11 Recruiting Nonmyeloablative Allogeneic Transplant
Conditions: Aplastic Anemia;   Paroxysmal Nocturnal Hemoglobinuria;   Acute Myelogenous Leukemia;   Acute Lymphocytic Leukemia;   Myelodysplastic Syndrome;   Chronic Myelogenous Leukemia;   Chronic Lymphocytic Leukemia;   Hodgkin's Lymphoma;   Non-Hodgkin's Lymphoma;   Mantle Cell Lymphoma;   Multiple Myeloma;   Waldenstrom Macroglobulinemia;   Breast Cancer;   Renal Cell Carcinoma;   Melanoma;   Sarcoma;   Ovarian Cancer;   Thymoma
Intervention: Procedure: Nonmyeloablative Allogeneic Transplant
12 Recruiting Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy
Conditions: Lymphoma;   Malignant Mesothelioma;   Malignant Pericardial Effusion;   Malignant Pleural Effusion;   Non-small Cell Lung Cancer;   Small Cell Lung Cancer;   Soft Tissue Sarcoma;   Thymoma and Thymic Carcinoma
Interventions: Drug: doxepin hydrochloride;   Other: placebo;   Procedure: quality-of-life assessment;   Other: questionnaire administration;   Other: laboratory procedure
13 Recruiting Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma
Condition: Thymic Carcinoma
Intervention: Drug: Milciclib Maleate
14 Recruiting Efficacy of Medical Treatment With SOM230 LAR in Patients With Primary Inoperable Thymoma and/or With Local Recurrent Thymoma to Reduce Tumor Size
Conditions: Primary Inoperable Thymoma;   Local Recurrent Thymoma
Intervention: Drug: SOM230 LAR
15 Recruiting Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy
Condition: Thymoma and Thymic Carcinoma
Intervention: Drug: Everolimus
16 Recruiting Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma
Conditions: Thymoma;   Thymic Carcinoma.;   Clinical Masaoka Stage II-IVA
Intervention: Drug: Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide
17 Recruiting Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy
Condition: Malignant Thymoma
Intervention: Drug: Milciclib Maleate
18 Recruiting Tumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas
Conditions: Mesolthelioma;   Esophageal Cancer;   Lung Cancer;   Thoracic Sarcomas
Interventions: Drug: Celecoxib;   Drug: ISCOMATRIX (TM) Adjuvant;   Biological: Autologous Tumor Cell Vaccine

Indicates status has not been verified in more than two years